| C07133-2026 |
| Title of Each Class | Number of Shares of Common Stock Outstanding and Amount of Debt Outstanding | |
|---|---|---|
| Common | 1,880,546,169 | |
| Treasury | 143,953,831 |
The Exchange does not warrant and holds no responsibility for the veracity of the facts and representations contained in all corporate disclosures, including financial reports. All data contained herein are prepared and submitted by the disclosing party to the Exchange, and are disseminated solely for purposes of information. Any questions on the data contained herein should be addressed directly to the Corporate Information Officer of the disclosing party.
Pryce CorporationPPC| Subject of the Disclosure |
|---|
PRYCE CORPORATION REMOVES PHARMACEUTICAL BUSINESS |
| Background/Description of the Disclosure |
Please see attached disclosure entitled, "PRYCE CORPORATION REMOVES PHARMACEUTICAL BUSINESS". |
| Other Relevant Information |
The SEC 17-C (Current Report) and the necessary Secretary's Certificates will be submitted to the Commission and PSE together with the corresponding Press Release. |
| Name | John Vherlin Magday |
|---|---|
| Designation | Compliance Officer |